GENE ONLINE|News &
Opinion
Blog

2021-09-05| Special

Feng Zhang’s Team Engineer “Ultra-Compact” Cas-13 To Solve Packaging and Delivery Issues of RNA Editors

by Manju Bhaskar
Share To
CRISPR-Cas13 is an RNA editing technique that can manipulate gene expression at the RNA level without modifying the genome. However, the delivery of RNA editors is perhaps the biggest barrier to the widespread adoption of this approach.

The therapeutic delivery of Cas13-based RNA editing systems remains challenging, in part because the size of Cas13-based RNA editors developed so far exceeds the packaging capacity of adeno-associated virus (AAV), the most widely used viral vector for gene delivery.

GO Prime with only $1.49 now

LATEST
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
2022-09-28
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
2022-09-28
Arsenal Biosciences Announced Another $70 million Collaboration, This Time With Genentech
2022-09-27
Sciwind Biosciences And SynerK Join Forces To Develop siRNA Therapeutics
2022-09-27
Acticor Enrolls First Patient in Phase 2/3 Stroke Treatment Study
2022-09-27
Daiichi Sankyo Wins Approval For Cancer Treatment in Japan
2022-09-26
Seagen Strikes Potential $650 million Deal with LAVA Therapeutics for Cancer Treatment
2022-09-26
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!